Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JNJ-61610588 (Onvatilimab) in Advanced Cancer
NCT02671955Phase 1Terminated
- Sponsor
- Janssen Pharmaceutical
- Start
- Jan 2016
- Primary completion
- Jan 2017
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label trial of onvatilimab in solid tumor (advanced stage), non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC) and 4 more (4 arms), sponsored by Janssen Pharmaceutical. Primary endpoints: Frequency of Dose Limiting Toxicity, Number of Participants with Adverse Events and Serious Adverse Events and 2 more. Started Jan 2016; status: terminated.
02
Drugs
onvatilimab
03
Conditions
solid tumor (advanced stage)non-small cell lung cancer (NSCLC)small cell lung cancer (SCLC)head and neck cancer (HNC)pancreatic cancer (PC)
Beyond the preview
Go deeper on NCT02671955.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02671955.